At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed renal cell carcinoma (clear cell, papillary, chromophobe, or sarcomatoid) not curable by standard approaches
- ✓Measurable disease by RECIST criteria
- ✓ECOG performance status 0 or 1
- ✓Life expectancy >3 months
- ✕Prior therapy with MAPK pathway or VEGFR inhibitors (including sunitinib, VEGF Trap, sorafenib, bevacizumab, temsirolimus, everolimus)
- ✕Prior anti-angiogenic therapy (sunitinib, VEGF Trap); sorafenib, bevacizumab, temsirolimus, everolimus not allowed as prior therapy
- ✕CNS metastases, except resected/radiosurgery with >6 months no progression if PI approves; prior meningioma allowed; controlled seizures allowed
- ✕Chemotherapy/immunotherapy within 4 weeks; monoclonal antibody within 8 weeks of treatment start
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Trial of BAY 43-9006 in Combination With Bevacizumab in Patients With Advanced Renal Cancer
In Brief
A Phase 2 clinical trial evaluating Bevacizumab, Sorafenib Tosylate, and 2 other interventions for Chromophobe Renal Cell Carcinoma and 5 related conditions. Completed, enrolled 73 participants across 5 sites.
Detailed Summary
This phase I/II trial studies the side effects and best dose of sorafenib tosylate and bevacizumab and to see how well they work in treating patients with advanced kidney cancer. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth by targeting certain cells. Bevacizumab and sorafenib tosylate may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving sorafenib tosylate together with bevacizumab may kill more tumor cells.
Study Details
Timeline
Interventions
Given IV
Given PO
Correlative studies
Correlative studies